Navigation Links
HistoRx and Lilly Extend, Expand AQUA(R) Analysis Partnership
Date:3/26/2008

-Agreement provides Lilly researchers broad access to HistoRx AQUA(R)

technology for tissue biomarker analysis-

NEW HAVEN, Conn., March 26 /PRNewswire/ -- HistoRx, Inc. announced today that it has signed a three-year agreement with Eli Lilly and Company (NYSE: LLY) to make the HistoRx AQUA(R) technology for tissue biomarker analysis widely available to Lilly researchers and clinicians involved in drug discovery, preclinical research, and clinical development. The agreement extends and significantly expands the scope of the collaboration established by HistoRx and Lilly in 2005 to apply the HistoRx AQUA(R) technology to help advance select Lilly pharmaceutical development programs. Under the new agreement, HistoRx will provide Lilly researchers broad access to the AQUA(R) technology for tissue biomarker analysis, and HistoRx will develop customized AQUA(R) analysis-based immunohistochemical assays for use in Lilly drug discovery and development projects. HistoRx has the option to commercialize the assays and reagents developed during the course of the partnership for clinical use as predictive diagnostics.

HistoRx provides pharmaceutical and biotechnology companies access to AQUA(R) technology through partnership agreements by which HistoRx works with the company in applying its hallmark quantitative, multiparametric, tissue- based biomarker measurement and analysis to drug development programs, virtually eliminating the subjective interpretation inherent in conventional immunohistochemical methods. In the course of the partnership, HistoRx develops AQUA(R) analysis-based diagnostic assays that are linked to its partners' drugs in development. HistoRx may then commercialize these assays as prognostic tests or
'/>"/>

SOURCE HistoRx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Lilly Announces Termination of AIR Insulin Program
2. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
3. Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration
4. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
5. Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar
6. Lilly Declares Fourth-Quarter Dividend
7. Emisphere Technologies, Inc. and Eli Lilly and Company Settle Ongoing Litigation
8. Neptune Technologies expands into medicinal markets in Asia Pacific
9. CMPMedica Expands SearchMedica.com with Multiple Additional Vertical Search Applications co-developed with Convera(R)
10. Nova Biosource Fuels Expands Senior Executive Team
11. FDA Clears Expanded Use of Xofts Axxent(R) Electronic Brachytherapy System for all Radiation Therapy Indications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... With a larger, brighter interface, ... Cole-Parmer® Digital Gear Pump Drive for Micropump® ... for automated process applications. , Simply set time ... count function counts down and displays batches completed ... dispensed across multiple cycles. View the four operating ...
(Date:7/21/2014)... (July 21, 2014) The yield so far ... have developed a low-energy, solution-based mineral substitution process to ... find use in electronics and alternative energy devices. , ... cover of the July 21 issue of the journal ... of research in the inorganic and nuclear chemistry fields. ...
(Date:7/21/2014)... Sleep disturbances such as insomnia, hypersomnia, ... depression. According to a study published by the ... of depressed patients have insomnia symptoms, and hypersomnia ... adults and 10% of older patients, with a ... have a major impact on quality of life, ...
(Date:7/19/2014)... 20, 2014 United States Non-Vascular ... GlobalDatas new report, "United States Non-Vascular Stents Market ... the United States Non-Vascular Stents market. The report ... (in units) and average prices (in US dollars) ... Stents and Metal Biliary Stents (Metal Non-Covered Biliary ...
Breaking Biology Technology:New Easy-View Cole-Parmer Digital Gear Pump Drive Makes Performance Monitoring Effortless 2Oregon chemists eye improved thin films with metal substitution 2Open Label Data on Enhanced Sleep Released by JayMac Pharmaceuticals, LLC 2Open Label Data on Enhanced Sleep Released by JayMac Pharmaceuticals, LLC 3United States Non-Vascular Stents Market Outlook to 2020 | Researchmoz 2United States Non-Vascular Stents Market Outlook to 2020 | Researchmoz 3United States Non-Vascular Stents Market Outlook to 2020 | Researchmoz 4
... Pharmaceuticals, Inc. (NYSE Amex: ANX ) today ... ended December 31, 2008."2008 was a transition year for ... focused on lower-risk reformulations of previously-approved drugs. We achieved ... the difficult economic environment, we were unable to attract ...
... Insmed Inc. (Nasdaq: INSM ), a developer of ... March 23, 2009, NASDAQ issued a notice further extending the ... price and those rules requiring a minimum market value of ... effect through Friday, July 17, 2009, and the original rules ...
... /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ... patient enrolment in its U.K. clinical trial to ... REOLYSIN(R) in combination with gemcitabine (Gemzar(R)) in patients ... neck. The principal investigators are Dr. Johann de ...
Cached Biology Technology:ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results 2ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results 3ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results 4ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results 5ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results 6ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results 7Insmed Announces That NASDAQ Further Extends Temporary Suspension of Minimum Bid Closing Price Rule 2Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial 2Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial 3
(Date:7/22/2014)... -- Stem cells offer much promise for treating damaged ... cell survival is poor, limiting their effectiveness. New methods ... and optimize their therapeutic function after transplantation, as described ... , a peer-reviewed journal from Mary Ann Liebert, Inc., ... BioResearch Open Access website . , ...
(Date:7/22/2014)... research has shown squirrels have adapted to New York ... well, if not better, than their fellow squirrels in ... Curtin,s Department of Environment & Agriculture, led the study ... their behaviour in urban environments and prevent unnecessary responses ... staying on the footpath. , "As we rapidly ...
(Date:7/22/2014)... of meerkats which sees them prevent their daughters from ... new study. , Research into the desert creatures which ... adult helpers shows that the alpha female can flourish ... study shows how this way of life, also found in ... despite its sinister side. , Dominant meerkats control breeding ...
Breaking Biology News(10 mins):New York squirrels are nuts about city life 2
... novel,vaccine that uses immune cells as factories to produce ... breast cancers, say researchers at,The University of Texas M. ... is a protein often present / surexpressed in ... Breast Cancer Research,on Nov. 29, 2004, showed that the ...
... NGEN), developer of advanced diagnostic products, announced today that ... Biologic Array" by the U.S. Patent and Trademark Office. ... one or more electrodes (or "test sites") across multiple ... covers a method for storing the value of the ...
... the Dana-Farber Cancer Institute report a surprising finding about ... only in the embryo itself, but also in the ... , Meticulous experiments in mice revealed that the placenta ... These cells, which appear very early in development, are ...
Cached Biology News:Gene Vaccine Protects Mice Against Development Of Her2/neu Breast Cancer 2Gene Vaccine Protects Mice Against Development Of Her2/neu Breast Cancer 3Nanogen Issued Patent for Electronic Microarray With Memory 2Placenta Is A Rich Source Of Blood Stem Cells 2
... anti-phospho-IRS1 (Tyr896) ... amino acid region encompassing the ... (Tyr896). Accession ... Quality Assurance: Routinely ...
Mouse monoclonal [YLI-90] to Ly49I (Biotin) ( Abpromise for all tested applications)....
CCNI Antibody...
Mouse monoclonal [LH8] to Cytokeratin 5 + 14 ( Abpromise for all tested applications). entrezGeneID: 3852 SwissProtID: P02533...
Biology Products: